Common Stock and Stockholders' Equity (Tables)

12 Months Ended

Mar. 31, 2019

Equity [Abstract]

Schedule of Shares of Common Stock Reserved for Future Issuance

The Company had reserved shares of common stock for future issuance pursuant to equity plans as follows (in thousands):

	As of March 31,
	2019	2018
Common stock options outstanding	2,751	3,215
RSUs outstanding	2,419	2,079
Available for future stock option and RSU grants	10,796	9,576
Available for future employee stock purchase plan awards	2,274	1,929
	18,240	16,799

Schedule of Stock Option and RSU Award Activities

The following table summarizes the Company’s stock option and RSU award activities for the fiscal year ended March 31, 2019 (in thousands, except exercise price, contractual term and fair value information):

	Options Outstanding							RSUs Outstanding
	Number of Shares		Weighted- Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value		Number of Shares		Weighted- Average Grant Date Fair Value		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding—April 1, 2018	3,215		$	22.79	6.7	$	165,041	2,079		$	42.31	2.7	$	154,071
Stock options granted	473		98.93
RSUs granted								1,532		98.74
Stock options exercised	(822	)	21.15			62,459
RSUs vested								(879	)	43.28
Stock options canceled/forfeited	(115	)	53.43
RSUs canceled/forfeited								(313	)	52.76
Outstanding - March 31, 2019	2,751		$	35.10	6.3	$	176,002	2,419		$	76.34	3.0	$	238,734
Options vested and expected to vest - March 31, 2019	2,728		$	34.59	6.3	$	175,803
Options vested and exercisable - March 31, 2019	1,921		$	20.02	5.3	$	151,259
RSUs expected to vest - March 31, 2019								2,232		$	74.52		$	220,294

Schedule of Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Shares to be Issued

The assumptions used to estimate the fair value of stock options granted and ESPP shares to be issued during the fiscal years ended March 31, 2019, 2018, and 2017 were as follows:

Stock Options:
	Year Ended March 31,
	2019	2018	2017
Expected term (years)	6	6	5 - 6
Expected volatility	41-42%	42 - 44%	46 - 47%
Risk-free interest rate	2.27-3.06%	1.86 - 2.74%	0.21 - 2.17%
Dividend yield	—	—	—
ESPP:
	Year Ended March 31,
	2019	2018	2017
Expected term (years)	0.5	0.5	0.5
Expected volatility	37-53%	29 - 30%	37 - 44%
Risk-free interest rate	2.23-2.50%	1.16 - 1.82%	0.46 - 0.67%
Dividend yield	—	—	—

Schedule of Cost of Revenue, Research and Development, Sales and Marketing and General and Administrative Expenses

Cost of revenue, research and development, sales and marketing, and general and administrative expenses were as follows (in thousands):

	Year Ended March 31,
	2019		2018		2017
Cost of revenue	$	3,487	$	2,440	$	1,847
Research and development	17,634		12,176		9,975
Sales and marketing	23,253		16,925		13,042
General and administrative	11,824		9,057		7,082
Total stock-based compensation expense	$	56,198	$	40,598	$	31,946